Literature DB >> 33211824

Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome.

Fatima Bawany1, Bushra Tbakhi2, Jason H Mendler2, Christopher T Richardson3, John M Bennett4, Omar S Aljitawi2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33211824      PMCID： PMC7686905          DOI： 10.1182/bloodadvances.2020003104

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

1.  Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

Authors:  Ronjon Chakraverty; Karl Peggs; Rajesh Chopra; Donald W Milligan; Panagiotis D Kottaridis; Stephanie Verfuerth; Johanne Geary; Dharsha Thuraisundaram; Kate Branson; Suparno Chakrabarti; Premini Mahendra; Charles Craddock; Anne Parker; Ann Hunter; Geoff Hale; Herman Waldmann; Catherine D Williams; Kwee Yong; David C Linch; Anthony H Goldstone; Stephen Mackinnon
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.

Authors:  B Sigurgeirsson; B Lindelöf; O Edhag; E Allander
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

3.  Changes in antibody titres in patients with anti-transcription intermediary factor 1-gamma antibody-positive idiopathic inflammatory myositis.

Authors:  Yoshiyuki Abe; Taiki Ando; Masakazu Matsushita; Kurisu Tada; Ken Yamaji; Naoto Tamura
Journal:  Rheumatology (Oxford)       Date:  2019-01-01       Impact factor: 7.580

4.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

Authors:  C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

5.  Refractory Dermatomyositis Complicated with Myelodysplastic Syndrome.

Authors:  Takashi Nakanishi; Hideyuki Horikoshi; Yasuyoshi Kusanagi; Takeshi Yamamura; Reiko Takahashi; Fumihiko Kimura; Kenji Itoh
Journal:  Intern Med       Date:  2015-10-01       Impact factor: 1.271

6.  Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.

Authors:  Manabu Fujimoto; Akihiro Murakami; Shunsuke Kurei; Naoko Okiyama; Atsushi Kawakami; Michiaki Mishima; Shinji Sato; Mariko Seishima; Takafumi Suda; Tsuneyo Mimori; Kazuhiko Takehara; Masataka Kuwana
Journal:  J Dermatol Sci       Date:  2016-09-23       Impact factor: 4.563

Review 7.  Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.

Authors:  Omar Al Ustwani; Laurie A Ford; Sheila J N Sait; Anne Marie W Block; Maurice Barcos; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Julian Ambrus; Meir Wetzler
Journal:  Leuk Res       Date:  2013-05-18       Impact factor: 3.156

8.  Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Authors:  David F Fiorentino; Lorinda S Chung; Lisa Christopher-Stine; Lisa Zaba; Shufeng Li; Andrew L Mammen; Antony Rosen; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2013-11

9.  Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

Authors:  J A Snowden; R Saccardi; M Allez; S Ardizzone; R Arnold; R Cervera; C Denton; C Hawkey; M Labopin; G Mancardi; R Martin; J J Moore; J Passweg; C Peters; M Rabusin; M Rovira; J M van Laar; D Farge
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

10.  Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment.

Authors:  Irina Lerman; Christopher T Richardson
Journal:  Cureus       Date:  2019-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.